Weekly Digest - February 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - February 2026
02 February 2026: AdvanCell announces collaboration and exclusive licensing agreement with 48Hour discovery to develop a novel peptide-based lead-212 radiotherapeutic for a gastrointestinal cancer with significant medical need
- AdvanCell has taken a strategic step to expand its targeted alpha therapy pipeline, announcing a collaboration and exclusive licensing agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (²¹²Pb) radiotherapeutic, initially focused on a gastrointestinal cancer with significant unmet medical need
- The partnership combines complementary strengths, bringing together 48Hour Discovery’s rapid peptide discovery platform with AdvanCell’s deep expertise in ²¹²Pb-based radioligand development, including secure isotope supply, scalable manufacturing, and clinical translation of targeted alpha therapies
- This collaboration is designed to accelerate development into the clinic, leveraging AdvanCell’s modular ²¹²Pb platform to create a repeatable and efficient pathway for advancing peptide-based radiotherapeutics, while also supporting the broader expansion of AdvanCell’s differentiated oncology pipeline
- Under the terms of the agreement, AdvanCell has secured exclusive worldwide rights to develop and commercialize the program, with plans to advance a second ²¹²Pb radiotherapeutic into the clinic in 2027, reinforcing the company’s confidence in its alpha-emitting technology following recently reported positive clinical results
- The deal further strengthens AdvanCell’s position in targeted alpha therapies, complementing its lead program ADVC001, a first-in-class ²¹²Pb-PSMA radioligand currently in Phase 1/2 development, and underscoring the company’s ambition to deliver transformative treatment options across large oncology markets with high medical need
